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ABSTRACT
Diabetes is a chronic disease, where the pancreas does not produce enough insulin or is not used
effectively, when not controlled, it can damage many organs. The objective was to describe the clinical
profile of patients diagnosed with type 2 diabetes mellitus. We conducted a descriptive, observational,
retrospective study between January and December 2019 in the area of consultation specialized in Integral
Medicine IPS (Cartagena, Colombia). Of the 23 patients studied, 47.8% were women and 52% were men.
39.1% of the population were between 50 and 59 years old, and 26.1% were overweight. It is concluded
that, most diabetic patients have a good control of their disease. However, they have a high comorbidity
and a high risk of Chronic Renal Disease and a high percentage of patients whose life expectancy does not
exceed 10 years, according to the Charlson Index.
Key words: Diabetes Mellitus Type 2; Comorbidity; Risk Factors; Glycated Hemoglobin A (HbA1c) (source:
MeSH NLM).

RESUMEN
La diabetes es una enfermedad crónica, donde el páncreas no produce insulina suficiente o no es utilizado
eficazmente, cuando no se controla, puede dañar muchos órganos. El objetivo fue describir el perfil
clínico de los pacientes diagnosticados con diabetes mellitus tipo 2. Realizamos un estudio descriptivo,
observacional, retrospectivo, entre enero y diciembre del 2019 en el área de consulta especializada en
Medicina Integral IPS (Cartagena, Colombia). De los 23 pacientes estudiados, el 47,8% era mujeres y
el 52,1% hombres. El 39,1% de la población tenían una edad comprendida entre 50-59 años, y el 26%
presentaban sobrepeso. Se concluye que, la mayoría de los pacientes diabéticos tienen un buen control
de su enfermedad. Sin embargo, presentan una alta comorbilidad y un elevado riesgo de Enfermedad
Renal Crónica y un alto porcentaje de pacientes cuya expectativa de vida no supera los 10 años, según el
Índice de Charlson.
Palabras clave: Diabetes Mellitus Tipo 2; Comorbilidad; Factores de Riesgo; Hemoglobina A Glicada
(HbA1c) (fuente: DeCS BIREME).

1 Latin American Lifestyle Medicine Association. Cartagena, Colombia.
2 Salud Ocupacional y Auditoria Medica de Colombia soamco. Barranquilla, Colombia.
3 Medicina Integral IPS. Cartagena, Colombia.
a
Internist, specialist in nutrition, diabetes and metabolism.
b
Epidemiologist.
Cite as: Eymard Torres, Helbert Arévalo, Idania Suarez, Narelcy Vega. Clinical profile of patients cared for type 2 diabetes in a reversion program.
Rev. Fac. Med. Hum. January 2021; 21(1):145-150. DOI 10.25176/RFMH.v21i1.3432
Journal home page: http://revistas.urp.edu.pe/index.php/RFMH
Artículo publicado por la Revista de la Facultad de Medicina Humana de la Universidad Ricardo Palma. Es un artículo de acceso abierto, distribuído bajo los
términos de la Licencia Creative Commons: Creative Commons Attribution 4.0 International, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), que
permite el uso no comercial, distribución y reproducción en cualquier medio, siempre que la obra original sea debidamente citada. Para uso comercial, por favor
póngase en contacto con revista.medicina@urp.pe

Published by INICIB-URP, 2021

Pág. 145

1

Revista de la Facultad de Medicina Humana, Vol. 21 [2021], Iss. 1, Art. 18

Rev. Fac. Med. Hum. 2021;21(1):145-150.

INTRODUCTION
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Diabetes Mellitus (DM) is currently one of the biggest
public health problems worldwide. According to the
World Health Organization (WHO), globally, from
1995 to the present, the patients diagnosed with
diabetes increased considerably, with the most
recent estimate of 347 million affected patients(1).
According to the International Diabetes Federation
(IDF), India, Brazil, China, Russia, the United States and
Mexico are the nations with the highest proportions
of patients with diabetes(2).
Diabetes is a chronic disease that occurs when the
pancreas produces insufficient insulin or is used
ineffectively. Manifesting clinically as hyperglycemia
(increased blood sugar), which over the years causes
serious damage to organs and systems, especially
nerves and blood vessels(3).
The IDF establishes that almost 10% of the global
population suffers from DM (382 million people),
and it is estimated that it increases to more than
590 million patients in a period of less than 25 years,
increasing by 55% (having into account that there
are at least 175 million sick people who have not yet
been diagnosed)(4).
In Colombia, during 2019, 186,568 new cases of DM
were diagnosed, 73,630 more than in 2018, of these
56.6% (n = 105,597) were female. Being the average
age of 61.84 years (SD ± 13.8), it was also observed
that 80.4% were between 50 and 75 years old and
3.6% were under 35 years old. Antioquia was the
territory that reported the highest incidence of DM
(n = 76 44, IA = 10.7}), followed by Bogotá, D.C. (n =
54,551, IA = 5.7) and Valle del Cauca (n = 40,943, IA
= 7.8). 80.4% of the new cases of DM were reported
by the entities of the contributory regime and 19.3%
by the entities of the subsidized regime, the E.P.S.
Sanitas reported the highest number of cases (n = 34
650 IA = 14.42) together with the E.P.S. Famisanar (n
= 28 840 IA = 18.2), the EPS Suramericana (n = 22 477
IA = 8.5) and Salud Total E.P.S. (n = 22 029 IA = 11.3(5).
Between July 2018 and June 2019, 1,294,940 people
diagnosed with DM were reported, meaning a
prevalence rate of 2.58 cases per 100 inhabitants,
which is equivalent to 85,462 more people than
the previous period. Of the total with DM diagnosis,
59.5% were women(5). During the time that the study
lasted, 27 656 deceased people diagnosed with DM
were reported, of all of them 55.1% (n = 15 238) were
women. The mortality rate for DM was estimated at
55.2 deaths per 100 000 inhabitants, being more in
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females (60.0) than in males (50.2) and the average
age of 76.26 years (SD ± 12, 2)(5).
Type 2 DM (DM2) is the main cause of various
conditions in adults who suffer from it, such as loss
of vision, kidney failure or diabetic foot, which can
cause the loss of the lower limbs(6). The increased
risk of cardiovascular problems is due to its
pathophysiology. A correct tertiary prevention based
on maintaining adequate metabolic control has a
close correlation with the reduction and delay in the
appearance of complications(7). DM2 is potentially
reversible; and even more so in the first years after
diagnosis(8). A research study in the United Kingdom
with people suffering from DM2 after a follow-up of
ten years, indicated a 37% decrease in the incidence
of microvascular complications, per percentage
point reduced in HbA1c(9). However, in other studies
this association was deficient(10,11).
The objective of this study was to describe the
clinical profile of patients cared for type 2 diabetes
mellitus in a reversion program.

THE STUDY
We carried out a retrospective descriptive
observational study, between January and
December 2019, in patient care, in the specialized
consulting office in Medicina Integral IPS (Cartagena,
Colombia).
Patients aged 18 years or more were included, having
received medical care in Medicina Integral IPS,
diabetes program, having registered consultations
on 01/01/2019 - 12/31/2019 with a diagnosis of DM2
in their clinical history (CH), with the code CIE10 E11,
and having registered at least once the HbA1c value
in the CH in the year to the date of recording the
data. Disenrolled persons were excluded before the
study began and while it was running.
Regarding the sampling, work was carried out with a
sample with replacement, until reaching the number
of patients calculated. The number of sample was
calculated from patients aged 18 years or older
cared with a diagnosis of DM2 during 2019, which
was 2,738 people, recorded with the CIE10 E11
coding in the CH. The number of patients required
with a diagnosis of DM2 to estimate a statistical
inference was 24 patients. To make this estimate,
work was carried out with a confidence level of 95%,
an expected prevalence of people with DM2, with
HbA1c less than 7%, of 15% (2,4,5,9-11); and with an
accuracy of ± 5%.

2

Torres Rodriguez et al.: Clinical profile trial of patients cared with diabetes
mellitus t
Clinical profile of patients cared for type 2 diabetes

Rev. Fac. Med. Hum. 2021;21(1):145-150.

Later date records of all characteristics evaluated
were gathered solely from the Fomplus electronic
medical record (EHR), individual service delivery
records, and the Diabetes Cartagena model feedback
database.
Between January and December 2019, the
participants were enrolled by communication via
telephone and in control of specialized medical
consultation appointments, where the objective of
the diabetes reversal program was explained and
a face-to-face appointment was arranged at the
headquarters of Medicina Integral IPS, Cartagena,
Colombia. Subsequently, the individual records and
the EHR of each participant were reviewed to collect
the last records of the study variables.

For adequate metabolic control, were considered
the indicators proposed as cardiovascular risk
factors (CVRF) according to the American Diabetes
Association (ADA)(11); which were total cholesterol
(TC) <185mg / dL, triglycerides (TG) <150md / dL,
HDL cholesterol> 40mg / dL in men and> 50mg / dL
in women, LDL cholesterol <100mg / dL, HbA1c <7%

Published by INICIB-URP, 2021

Comorbidities were measured using the Charlson
index(12). Likewise, records of arterial hypertension
(AHT) and progression of CKD (kidney disease)
were collected, since they are highly relevant when
evaluating the level of metabolic control in patients
with DM2.
For the statistical analysis, a descriptive analysis was
performed; to describe the quantitative variables,
means were used and for the qualitative variables,
the proportions; both with their respective 95%
confidence intervals. The Shapiro-Wilk test was used
to evaluate the distribution of normality. Statistical
analysis was performed with R software (https://
cran.r-project.org/).

FINDINGS
24 patients were listed, of which 1 is disenrolled
during the course of the study. Of the 23 participants,
47.8 were female and 52.1% male. 39.1% of the
sample were between 50-59 years old, and 26.1%
were overweight. The other characteristics are
shown in table 1.
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Sociodemographic characteristics were collected,
such as age and sex; and anthropometric, such as
weight and height and, based on these, the body
mass index (BMI).

, blood pressure (BP) <140 / 90mmHg, systolic blood
pressure (SBP) <140mmHg, and diastolic blood
pressure (DBP) <90mmHg.
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Table 1. Sociodemographic and anthropometric characteristics of the population. Integral Medicine,
Cartagena, 2019.
Variable

n

Value

95% CI

Woman (%)

11

47.8

42.8-56.7

Man (%)

12

52.1

43.3-57.2

Mean

23

57.7

68.1-71.5

<50 years (%)

4

17.4

50 – 59 years (%)

9

39.1

60 – 69 years (%)

7

30.4

70 – 79 years (%)

2

8.7

Sex

Age (years)

≥80 years (%)

ORIGINAL SHORT

1

4.3

Height cm (mean)

23

161.1

160.4-163.2

Weight kg (mean)

23

81.5

78.3-83.2

23

28.6

29.9-31.5

Mean

BMI kg/m2

Underweight (%)

1

4.3

<15-18.4

Normal weight (%)

8

34.8

18.5-24.9

Overweight (%)

6

26.1

25-29.9

Obesity class I (%)

5

21.7

30-34.9

Obesity class II (%)

2

8.7

35-39.9

Morbid obesity (%)

1

4.3

>40

BMI: Body Mass Index

95.7% of the participants had an HbA1c value lower
than 7.0%. 78.3% had a diagnosis of hypertension
(95% CI 66.7-79.0), and 45% dyslipidemia (DLP)

(95% CI 60.8-73.9). Table 2 shows the characteristics
related to comorbidities and metabolic control.

Table 2. Metabolic control and comorbidity of the population. Integral Medicine, Cartagena, 2019.
Variable
Arterial Blood Pressure

Glycated hemoglobin
percentage
LDL cholesterol

n

Value

95% CI

SBP mmHg (media)

23

120.9

122.1-136.8

DBP mmHg (media)

23

73.1

75.5-78.3

BP < 140/90 mmHg (%)

23

100.0

Mean

23

6.1

HbA1c < 7,0% (%)

22

95.7

HbA1c < 7,5% (%)

1

4.3

Mean (mg/dL)

20

174.3

< 100 mg/dL (%)

9

45.0

Mean (mg/dL)

21

105.1

49.6-53.1

Men (media)

11

52.4

44.1-48.7

Women (media)

10

47.6

54.2-58.7

Mean (mg/dL)

15

47.9

129.1-152.2

< 150 mg/dL (%)

0

0.0

18

78.3

66.7-79.0

Points (mean)

23

4.4

2.6-3.0

Charlson index (mean)

23

32.0

Absence of comorbidity (%)

0

0.00

Low comorbidity (%)

4

17.4

High comorbidity (%)

19

82.6

HDL cholesterol

Triglycerides

AHT (%Si)

Charlson comorbidity
index

6.8-7.1
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DISCUSSION
As observed in this study, although most of the
participants have adequate control of DM2's glucose
and values of cholesterol and triglycerides in the
blood, a large percentage have a very high risk of
chronic renal disease progression.
The results of the social and demographic data are
similar to those found by other researchers who
use very similar variables(7,11). It could be explained,
in a general way, because in patients with DM2,
the programs are aimed at typical patients, whose
characteristics include an age close to 50 years of
age and the presence of other diseases, such as
hypertension, dyslipidemia, etc.

In this group of patients, more than half of the study
subjects have obesity. For this reason, the diabetes
reversal program is focused on lifestyle modifications
so that, pathophysiologically, aging decreases by
increasing physical activity and favoring changes in
diet, reducing the consumption of saturated fat and
simple carbohydrates(13). Therefore, following the
suggestions of the ADA 2016, it is essential to face
obesity to have better glycemic control(12).
It might be said that the study's patients have good

Published by INICIB-URP, 2021

Adequate control of DM2 must adhere to the
particular goals of HbA1c values in each person,
to avoid treatments that do not show significant
progress. It is preferable that the personalization of the
metabolic control objectives be taken into account,
according to the specific and individual conditions
of each patient, such as age, comorbidities, time of
illness, risk of cardiovascular disease or kidney disease.
Also in future research, a larger study population will
be necessary to address and better understand the
degree of individual control of HbA1c. Within the
limitations of the present study, a limited sample size
was shown.

ORIGINAL SHORT

Regarding the control of serum glucose by estimating
HbA1c, the ADA urges, for adequate control, trying to
maintain values below 7.0%(12). Emphasizing that the
majority of the population of the Diabetes Reversion
Program would be showing, according to the ADA
guidelines, adequate metabolic control.

control over their blood pressure values, according
to the suggestions of the ADA 2016(12), which advises
having values below 140 mmHg of SBP and below 90
mmHg of DBP. Regarding the control of triglycerides
and total cholesterol, more than 50% of the
participants had good control; while less than 50%
reached an LDL cholesterol value lower than 100mg
/ dL, however, the mean of the HDL cholesterol values
exceeds the mean in the suggested limits (>40 mg /dL
in men and >50mg /dL in women).

CONCLUSION
Most diabetic patients have adequate control of their
disease. However, they present a high comorbidity,
a high risk of Chronic Kidney Disease and a high
percentage of patients whose life expectancy does
not exceed 10 years, following the Charlson Index
method.
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